SCHEMBL5420741

SCHEMBL5420741

CNCc1ccc(-c2ccn3c(=O)c(C(=O)O)cc(C4CC4)c3c2C)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.33
AGTR2 P50052 1/20 0.33
CAMKK2 Q96RR4 2/20 0.33
AVPR1B P47901 1/20 0.33
CAMKK1 Q8N5S9 1/20 0.33
LTB4R2 Q9NPC1 1/20 0.32
PIK3CA P42336 1/20 0.32
MTOR P42345 1/20 0.32
PPARG P37231 7/20 0.32
KDM4C Q9H3R0 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
PKM P14618 1/20 0.31
BRD4 O60885 1/20 0.31
FAAH O00519 1/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
ABHD12 Q8N2K0 1/20 0.31
PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5422240 0.90 CD274 (0.36) AGTR1AGTR2CAMKK2CAMKK1PPARG
SCHEMBL5426457 0.90 CAMKK1 (0.34) AGTR1AGTR2CAMKK2CAMKK1LTB4R2
SCHEMBL12502388 0.90 KMT2A (0.37) AGTR1AGTR2CAMKK2CAMKK1LTB4R2
SCHEMBL1290163 0.90 AGTR1 (0.35) AGTR1AGTR2CAMKK2CAMKK1PPARG
SCHEMBL5416290 0.90 AVPR1B (0.40) CAMKK2AVPR1BCAMKK1PIK3CAMTOR
SCHEMBL22641572 0.90 AGTR1 (0.32) AGTR1AGTR2CAMKK2CAMKK1LTB4R2
SCHEMBL20960274 0.90 PPARG (0.33) AGTR1AGTR2CAMKK2CAMKK1PPARG
SCHEMBL20083150 0.89 S1PR1 (0.36) AGTR1AGTR2CAMKK2CAMKK1PPARG
SCHEMBL5426746 0.89 KDM4E (0.39) KDM4EALDH1A1GAA
SCHEMBL1290213 0.88 AGTR1 (0.34) AGTR1AGTR2CAMKK2AVPR1BCAMKK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223773-B2 4-oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SALO PHARMACEUTICAL CO., LTD. (JP) 2007-05-29 US disclosed
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SATO PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
EP-1437354-A1 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETON AS PARTIAL STRUCTURE Sato Pharmaceutical Co. Ltd. (JP) 2004-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229903-A1 4-Oxoquinolizine antibacterial agent having 2-pyridone skeleton as partial structure SDHA, IL4I1, BLVRB AGTR1 170/4885AGTR2 289/4885CAMKK2 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.